Loading organizations...
Based in Schlieren, Switzerland, Centenara Labs is an integrated biotechnology platform company that funds and incubates startups developing therapies to promote healthy aging and prolong human lifespan. Operating under a hub-and-spoke business model, the firm provides capital and coaching to entrepreneurial scientists to co-create treatments targeting age-related conditions such as cellular senescence and muscle wasting. The organization's diversified portfolio includes clinical-stage biotechnology companies such as Endogena, which focuses on retinitis pigmentosa, and Rejuvenate Biomed, which targets sarcopenia. Centenara Labs advances its internal research and development programs with financial backing from institutional investors including Apeiron Investment Group and Catalio Capital. The firm's scientific approach specifically builds upon foundational proof-of-principle research regarding senescent cell clearance originally published in a 2011 Nature study. Originally operating under the name Rejuveron, the company was founded in 2019 by Christian Angermayer and Matthias Steger.
Centenara Labs has raised $75.0M across 1 funding round.
Centenara Labs has raised $75.0M in total across 1 funding round.
Centenara Labs has raised $75.0M across 1 funding round. Most recently, it raised $75.0M Series B in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $75M Series B | — | Define Ventures, Dragoneer Investment Group, Mubadala, Ayman Alabdallah | Announced |
Centenara Labs has raised $75.0M in total across 1 funding round.
Centenara Labs's investors include Define Ventures, Dragoneer Investment Group, Mubadala, Ayman AlAbdallah.
Centenara Labs is a clinical-stage biotechnology company developing therapies that target the hallmarks of aging to expand human healthspan and address geriatric diseases like cancer, fibrosis, sarcopenia, and retinal degeneration.[1][3][5] Operating as a "hub and spoke" model, it builds a diversified pipeline through internal development and portfolio companies such as Endogena Therapeutics (clinical-stage for eye diseases via stem cell activation) and RejuverSen (pre-clinical senolytics for cancer and fibrosis), serving the healthcare and pharmaceutical sectors amid rising global aging populations.[1][2][5] With $101.13M raised in Series B funding as of 2023, it focuses on high-unmet-need areas like triple-negative breast cancer, IPF/CKD fibrosis, telomere restoration, and vascular cognitive decline, aiming to reduce healthcare burdens through breakthrough therapeutics.[3][5]
Centenara Labs, formerly Rejuveron Life Sciences, was founded in 2019 and is headquartered in Zurich, Switzerland.[3][4] It emerged from a vision to translate aging research into drugs, backed by entrepreneur Christian Angermayer of Apeiron Investment Group, who brings 20+ years in life sciences and deep tech, alongside Etienne (25+ years in healthcare fundraising) and scientific leaders like a University of Paris Cité professor known for mitochondrial research in cell death.[4] Pivotal early traction included a $75M Series B and convertible loan in September 2023, rebranding to Centenara Labs, and advancing assets like Endogena's EA-2353 for retinitis pigmentosa into clinical stages while building pre-clinical programs in senolytics and telomeres.[1][3][6]
Centenara Labs rides the longevity biotech wave, targeting aging's root hallmarks (e.g., senescence, telomere attrition) as global populations age, straining healthcare with diseases like IPF, CKD, and sarcopenia.[1][5] Timing aligns with advances in senolytics and regenerative medicine, fueled by market forces like increased life expectancy and investor interest in healthspan extension (e.g., post-2023 funding surge).[3] It influences the ecosystem by de-risking early discoveries into clinical assets, partnering with specialists like Endogena, and pioneering multi-indication therapies that could expand to broader age-related conditions, accelerating industry shift from symptom treatment to reversal.[2][4]
Centenara Labs is poised for milestone catalysts, including RejuverSen's 2025 IND entry for breast cancer and fibrosis programs, alongside telomere and vascular advances potentially yielding first-in-class approvals.[1][5] Rising AI-driven drug discovery and longevity funding trends will amplify its momentum, evolving it from pipeline builder to multi-asset leader in healthspan therapies. As aging demographics intensify, its hub model could redefine biotech efficiency, delivering on the promise of healthier, longer lives that hooked us from the start.[2][3]
